{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T03:44:33Z","timestamp":1772163873653,"version":"3.50.1"},"reference-count":16,"publisher":"BMJ","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Clin Pathol"],"published-print":{"date-parts":[[2010,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\u2018Triple-negative\u2019 is traditionally used to define a specific subtype of breast cancer with negative oestrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor-type 2 (HER2) expressions. ER\/PR and HER2 testing is also widely used in the informative classification of ovarian cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To investigate whether a \u2018triple-negative\u2019 subtype also exists in ovarian cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>ER, PR and HER2 expressions in 116 Chinese women with primary epithelial ovarian cancer were reviewed. Triple-negative epithelial ovarian cancer (TNEOC) was defined based on negative ER, PR and HER2 expression. The clinicopathological characteristics and Ki-67, P53 and epidermal growth factor receptor (EGFR) expression in the TNEOC and non-TNEOC group were compared.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>15.5% of cases (18\/116) were identified as TNEOC among 116 ovarian carcinomas. Histological grade 3 was found in a higher percentage of the TNEOC than of the non-TNEOC group (94.4% vs 62.2%). TNEOC also correlated with a high level of Ki-67 and p53 expression. EGFR overexpression and other clinicopathological characteristics were not significantly associated with TNEOC subtype. TNEOC was associated with a shorter progression free survival and overall survival in univariate and multivariate analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>A novel subtype of ovarian carcinoma, which is negative for ER, PR and HER2 expression, has been identified; this specific ovarian subtype tends to have aggressive characteristics and a poor prognosis, which is similar to triple-negative breast cancer in most respects. TNEOC should be considered in future investigations of informative classification of ovarian cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jcp.2009.071985","type":"journal-article","created":{"date-parts":[[2010,3,4]],"date-time":"2010-03-04T11:19:48Z","timestamp":1267701588000},"page":"240-243","source":"Crossref","is-referenced-by-count":15,"title":["The clinicopathological characteristics of \u2018triple-negative\u2019 epithelial ovarian cancer"],"prefix":"10.1136","volume":"63","author":[{"given":"Naifu","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingwu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiugui","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2010,3,4]]},"reference":[{"key":"2025121403261182000_63.3.240.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3835(02)00686-9"},{"key":"2025121403261182000_63.3.240.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2004.11.010"},{"key":"2025121403261182000_63.3.240.3","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-008-0213-x"},{"key":"2025121403261182000_63.3.240.4","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.2002.6620"},{"key":"2025121403261182000_63.3.240.5","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/j.1365-2559.2007.02889.x","article-title":"Triple negative tumours: a critical review","volume":"52","author":"Reis-Filho","year":"2008","journal-title":"Histopathology"},{"key":"2025121403261182000_63.3.240.6","first-page":"1233","article-title":"Understanding and treating triple-negative breast cancer","volume":"22","author":"Anders","year":"2008","journal-title":"Oncology (Williston Park)"},{"key":"2025121403261182000_63.3.240.7","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/j.1471-0528.1989.tb03341.x","article-title":"Revised FIGO staging for gynaecological cancer","volume":"96","author":"Shepherd","year":"1989","journal-title":"Br J Obstet Gynaecol"},{"key":"2025121403261182000_63.3.240.8","first-page":"5","article-title":"World Health Organization classification and nomenclature of ovarian cancer","volume":"42","author":"Scully","year":"1975","journal-title":"Natl Cancer Inst Monogr"},{"key":"2025121403261182000_63.3.240.9","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.1994.1346"},{"key":"2025121403261182000_63.3.240.10","first-page":"16","volume-title":"WHO handbook for reporting results of cancer treatment","volume":"vol. 48","author":"World Health Organization","year":"1979"},{"key":"2025121403261182000_63.3.240.11","doi-asserted-by":"publisher","DOI":"10.1186\/bcr915"},{"key":"2025121403261182000_63.3.240.12","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22618"},{"key":"2025121403261182000_63.3.240.13","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-3045"},{"key":"2025121403261182000_63.3.240.14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.5664"},{"key":"2025121403261182000_63.3.240.15","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22381"},{"key":"2025121403261182000_63.3.240.16","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-8-307"}],"container-title":["Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jcp.2009.071985","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T11:26:19Z","timestamp":1765711579000},"score":1,"resource":{"primary":{"URL":"https:\/\/jcp.bmj.com\/lookup\/doi\/10.1136\/jcp.2009.071985"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3]]},"references-count":16,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2010,3,4]]},"published-print":{"date-parts":[[2010,3]]}},"alternative-id":["10.1136\/jcp.2009.071985"],"URL":"https:\/\/doi.org\/10.1136\/jcp.2009.071985","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.2478976.2118077","asserted-by":"object"}]},"ISSN":["0021-9746","1472-4146"],"issn-type":[{"value":"0021-9746","type":"print"},{"value":"1472-4146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,3]]}}}